-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tislelizumab in Metastatic Hepatocellular Carcinoma (HCC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tislelizumab in Metastatic Hepatocellular Carcinoma (HCC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tislelizumab in Metastatic Hepatocellular Carcinoma (HCC) Drug Details: Tislelizumab...
-
Product Insights
Bronchiectasis – Drugs In Development, 2023
Global Markets Direct’s, ‘Bronchiectasis - Drugs In Development, 2023’, provides an overview of the Bronchiectasis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Bronchiectasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Lupus Nephritis – Drugs In Development, 2023
Global Markets Direct’s, ‘Lupus Nephritis - Drugs In Development, 2023’, provides an overview of the Lupus Nephritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Lupus Nephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Acute Lung Injury – Drugs In Development, 2023
Global Markets Direct’s, ‘Acute Lung Injury - Drugs In Development, 2023’, provides an overview of the Acute Lung Injury pipeline landscape. The report provides comprehensive information on the therapeutics under development for Acute Lung Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Respiratory Distress Syndrome – Drugs In Development, 2023
Global Markets Direct’s, ‘Respiratory Distress Syndrome - Drugs In Development, 2023’, provides an overview of the Respiratory Distress Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Respiratory Distress Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Acute Respiratory Distress Syndrome – Drugs In Development, 2023
Global Markets Direct’s, ‘Acute Respiratory Distress Syndrome - Drugs In Development, 2023’, provides an overview of the Acute Respiratory Distress Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Acute Respiratory Distress Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Sepsis – Drugs In Development, 2023
Global Markets Direct’s, ‘Sepsis - Drugs In Development, 2023’, provides an overview of the Sepsis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Sepsis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LY-3532226 in Type 2 Diabetes
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LY-3532226 in Type 2 Diabetes report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LY-3532226 in Type 2 Diabetes Drug Details: LY-3532226 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CNP-201 in Peanut Allergy
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.CNP-201 in Peanut Allergy Drug Details:CNP-201 is under development for the treatment of peanut allergy. The...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MSB-6005 in Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MSB-6005 in Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.MSB-6005 in Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair)Drug Details:MSB-6005...